Meiotic cell cycle checkpoint signaling

pathway activity — tumor vs normal
GO:0033313Tumor vs NormalRNA activityBox plot · TCGA cohorts

Across TCGA pan-cancer cohorts, RNA activity of the Meiotic cell cycle checkpoint signaling pathway differs between tumor and matched normal tissue in 16 of the 18 cancer types tested.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors.

KIRC, LUAD, and BLCA show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log2 scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.
LineageGenderStageActivity changepSampling consensus
KIRCFemaleII,III,IV+0.067<.00112view →
LUADMaleIII,IV+0.170<.00111view →
BLCAMaleIII,IV+0.145<.00111view →
KIRPAllIII,IV+0.110<.00111view →
KICHAllIII,IV+0.107<.00111view →
LUSCAllIII,IV+0.170<.0019view →
UCECAllIII,IV+0.163<.0018view →
LIHCMaleAll+0.054<.0017view →
HNSCAllAll+0.047<.0017view →
BRCAAllII,III,IV+0.118<.0016view →
COADAllAll+0.032.0026view →
STADAllAll+0.060.0093view →
Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 16 lineages.

GO:0033313–KIRC

Tumor-vs-normal pathway-activity box plot for Meiotic cell cycle checkpoint signaling in KIRC.

Open the KIRC breakdown →

Exploration